PatientsVille.com LogoPatientsVille.com

Stroke | Study of Procoagulation Markers in Stroke Patients

Stroke research study

What is the primary objective of this study?

The Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT): Response to Insulin Administration and Blood Glucose Control proposal is designed to accompany the Stroke Hyperglycemia Insulin Network Effort (SHINE) clinical trial, a Phase III multicenter, randomized, controlled trial planning to determine the efficacy and validate the safety of glycemic control in stroke patients. The SHINE trial will recruit 1,400 AIS patients with Type II diabetes mellitus (T2DM) and hyperglycemia, each receiving 3 days of hyperglycemia control with intravenous (IV) insulin therapy or control therapy with subcutaneous (SQ) insulin. The I-SPOT trial will recruit 315 SHINE patients. Blood coagulation marker levels will be measured before and at 48 hours after the start of treatment. Baseline and temporal changes in biomarkers levels will be compared between treatment groups. Hypothesis: The decrease in levels of markers of blood coagulation will be greater in patients treated with IV insulin to reduce BG than in patients treated with SQ Insulin as the standard fashion. Hypothesis: The decrease in levels of markers of blood coagulation will be greater in patients with than without favorable (SHINE) outcome (defined as the baseline stroke severity adjusted measure of functional ability at 90 days after AIS). Hypothesis: Hyperglycemia control modulates the relationship between blood coagulation levels and functional outcome in T2DM patients after stroke. Patients treated with IV Insulin for hyperglycemia control with favorable (SHINE) outcome will have greater decreases in blood coagulation levels than either IV Insulin-treated patients without favorable outcome or SQ Insulin-treated with or without favorable outcomes at 90 days after AIS.

Who is eligible to participate?

Inclusion Criteria: - Enrolled in SHINE study - Ability to give Informed Consent (self or LAR) Exclusion Criteria: - Current or planned use of full dose anticoagulation from baseline to the 48 hour sample collection - Known moderate or severe hepatic insufficiency (as defined by INR>1.5 if known or history of variceal bleeding or hepatic encephalopathy) - Prior or concurrent thrombotic or hypercoagulable condition (Antiphospholipid antibody syndrome; Antithrombin III, Protein C or S deficiencies; Congenital or Inherited Factor deficiencies; sickle cell disease)

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Stroke

Hyperglycemia

Procoagulation Markers

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Other:Glycemic Control

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

SHINE study subjectsSubjects enrolled in the SHINE trial who are not receiving intra-arterial therapy nor systemic anticoagulation; have no known moderate/severe hepatic insufficiency; have no known history of hypercoaguable or thrombotic condition; have INR =<1.5 (if known) at baseline and provide informed consent (self or LAR) will be enrolled in the I-SPOT study.

Study Status

Recruiting

Start Date: August 2012

Completed Date: August 2017

Phase: N/A

Type: Observational

Design:

Primary Outcome: change in biomarker between patients with favorable versus unfavorable functional outcome

Secondary Outcome: Changes in biomarker levels between patients with versus without stroke recurrence at 90 days post stroke.

Study sponsors, principal investigator, and references

Principal Investigator: Nina T Gentile, M.D.

Lead Sponsor: Temple University

Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)

More information:https://clinicaltrials.gov/show/NCT01811550

Discuss Rash